Valuing Health States When Transitioning From Stage 2 to Stage 3 Type 1 Diabetes in a Sample of the General Population in the United Kingdom
Author(s)
Oliver Guenther, PhD1, Omar Alsaleh Abdul Jabbar, PharmD, MHEcon2, Mireille Bonnemaire, MD1, Aymeric Mahieu, PharmD1, Helen Mitchell, BSc3, Charlie Nicholls, PhD3.
1Sanofi, Paris, France, 2Sanofi, Milan, Italy, 3Sanofi, Reading, United Kingdom.
1Sanofi, Paris, France, 2Sanofi, Milan, Italy, 3Sanofi, Reading, United Kingdom.
OBJECTIVES: Type 1 diabetes (T1D) is a chronic disease that can be detected before clinical symptoms appear. Disease-modifying therapies (DMTs) such as Teplizumab, have shown potential to delay the progression from stage 2 (presymptomatic) to stage 3 (symptomatic) T1D. Delaying T1D onset may reduce resource use and improve health-related quality of life (HRQoL). While HRQoL is known to decline after symptom onset, it remains unknown whether individuals with presymptomatic T1D experience similar HRQoL as the general population. This study examined HRQoL across T1D progression stages using hypothetical vignettes.
METHODS: This cross-sectional study included a representative sample of the United Kingdom (UK) general population (aged ≥18 years). Participants were split into two groups: Group-A was introduced to a vignette describing the progression from stage 2 to stage 3 with a hypothetical DMT that can delay the onset of stage 3; Group-B was introduced to the same vignette but without treatment. Participants assessed their current health state, and the vignette-inspired hypothetical health statuses in stages 2 and 3 using the EQ-5D-5L questionnaire. HRQoL scores were converted to social preference values (EQ-5D index UK). Descriptive and parametric statistics (p<0.05 indicating statistical significance) were used.
RESULTS: A total of 300 participants (mean age: 42.5 years; 90% Caucasians) were included (n=150, each group). The mean EQ-5D index for the individuals’ own health status was 0.837. When hypothetically progressed to stage 2, EQ-5D index declined in both groups (Group-A vs Group-B: 0.782 vs 0.720), with a significantly smaller reduction in those anticipating the potential delay-of-stage 3 onset benefits of a DMT (−0.049 vs −0.124; p=0.004); health status declined with hypothetical progression to stage 3 (0.553 vs 0.527).
CONCLUSIONS: Participants rated pre-symptomatic T1D with lower HRQoL than the general population, and clinical T1D even lower. The availability of a DMT was associated with higher HRQoL compared to natural progression.
METHODS: This cross-sectional study included a representative sample of the United Kingdom (UK) general population (aged ≥18 years). Participants were split into two groups: Group-A was introduced to a vignette describing the progression from stage 2 to stage 3 with a hypothetical DMT that can delay the onset of stage 3; Group-B was introduced to the same vignette but without treatment. Participants assessed their current health state, and the vignette-inspired hypothetical health statuses in stages 2 and 3 using the EQ-5D-5L questionnaire. HRQoL scores were converted to social preference values (EQ-5D index UK). Descriptive and parametric statistics (p<0.05 indicating statistical significance) were used.
RESULTS: A total of 300 participants (mean age: 42.5 years; 90% Caucasians) were included (n=150, each group). The mean EQ-5D index for the individuals’ own health status was 0.837. When hypothetically progressed to stage 2, EQ-5D index declined in both groups (Group-A vs Group-B: 0.782 vs 0.720), with a significantly smaller reduction in those anticipating the potential delay-of-stage 3 onset benefits of a DMT (−0.049 vs −0.124; p=0.004); health status declined with hypothetical progression to stage 3 (0.553 vs 0.527).
CONCLUSIONS: Participants rated pre-symptomatic T1D with lower HRQoL than the general population, and clinical T1D even lower. The availability of a DMT was associated with higher HRQoL compared to natural progression.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
PCR263
Topic
Patient-Centered Research
Topic Subcategory
Health State Utilities
Disease
Diabetes/Endocrine/Metabolic Disorders (including obesity), No Additional Disease & Conditions/Specialized Treatment Areas